- Home
- PMNT vs DMAC Comparison
PMNT vs DMAC Comparison
Compare PMNT & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMNT
- DMAC
- Stock Information
- Founded
- PMNT 1984
- DMAC 2000
- Country
- PMNT United States
- DMAC United States
- Employees
- PMNT N/A
- DMAC N/A
- Industry
- PMNT
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- PMNT
- DMAC Health Care
- Exchange
- PMNT NYSE
- DMAC Nasdaq
- Market Cap
- PMNT 18.0M
- DMAC 178.0M
- IPO Year
- PMNT 2024
- DMAC N/A
- Fundamental
- Price
- PMNT $0.30
- DMAC $3.63
- Analyst Decision
- PMNT Strong Buy
- DMAC Strong Buy
- Analyst Count
- PMNT 1
- DMAC 2
- Target Price
- PMNT $6.00
- DMAC $8.00
- AVG Volume (30 Days)
- PMNT 4.6M
- DMAC 326.6K
- Earning Date
- PMNT 08-13-2025
- DMAC 08-06-2025
- Dividend Yield
- PMNT N/A
- DMAC N/A
- EPS Growth
- PMNT N/A
- DMAC N/A
- EPS
- PMNT N/A
- DMAC N/A
- Revenue
- PMNT $21,501,000.00
- DMAC N/A
- Revenue This Year
- PMNT $52.76
- DMAC N/A
- Revenue Next Year
- PMNT N/A
- DMAC N/A
- P/E Ratio
- PMNT N/A
- DMAC N/A
- Revenue Growth
- PMNT N/A
- DMAC N/A
- 52 Week Low
- PMNT $0.22
- DMAC $3.00
- 52 Week High
- PMNT $2.15
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- PMNT N/A
- DMAC 44.55
- Support Level
- PMNT N/A
- DMAC $3.48
- Resistance Level
- PMNT N/A
- DMAC $3.88
- Average True Range (ATR)
- PMNT 0.00
- DMAC 0.26
- MACD
- PMNT 0.00
- DMAC 0.00
- Stochastic Oscillator
- PMNT 0.00
- DMAC 30.10
About PMNT PERFECT MOMENT LTD
Perfect Moment Ltd is a company which is a luxury lifestyle brand that combines fashion and technical performance for its ranges of skiwear, outerwear, swimwear, and activewear. It operates at the intersection of luxury fashion and multi-channel commerce. Although the Company is organized fundamentally as one business segment which is product sales, the Company's revenues are primarily split between three geographic areas which are the U. S., Europe, and the UK.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.